Deferasirox (ICL670): from bench to bedside

Published: May 29, 2009
Abstract Views: 214
PDF: 649
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

This document accompanies the presentation by Dr Daniele Alberti, Clinical Program Leader, Novartis Pharma. The presentation provides an overview of the drug development process and refers, by way of illustration, to a case history of a Novartis compound currently completing clinical development.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Alberti, D. (2009). Deferasirox (ICL670): from bench to bedside. Hematology Meeting Reports (formerly Haematologica Reports), 1(8). https://doi.org/10.4081/hmr.v1i8.273